Stockreport

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Guardant Health, Inc.  (GH) 
Last guardant health, inc. earnings: 2/24 04:03 pm Check Earnings Report
PDF First FDA-approved CDx for Guardant360 CDx in colorectal cancer further expands its role in guiding targeted therapy across solid tumorsApproval supported by data from P [Read more]